AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06030388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity aerobic training
Description: Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.
Study NCT06783101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of smart inhaler to enhance asthma inhaler proficiency
Description: The application of the smart inhaler technology to enhance asthma inhaler proficiency
Study NCT06783270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL therapy
Description: Compared to traditional TIL-therapy, this study will include silencing of the PD-1 coding gene in the TILs using non-viral CRISPR-Cas9 prior to the rapid expansion protocol.
Study NCT06787469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin Cement
Description: Bioactive self adhesive resin cement (SHOFU BeautiLink) used to cement indirect restorations to endodontically treated molars.
Study NCT06787469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin Cement
Description: Self adhesive resin cement
Study NCT06787989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CD19 cCAR T cells
Description: • BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study NCT06785259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress(MIED)
Description: Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study NCT06787261 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: saliva sample
Description: saliva sample
Study NCT06787261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: saliva sample
Study NCT06787261 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: carious tissue samples
Description: carious tissue samples
Study NCT06786897 — intervention group
Intervention type: OTHER
Intervention: Questionnaire and Physical Exam
Description: Questionnaires evaluating the expectations of patients in palliative situation, of paramedics and medical staff, concerning blood cell transfusions.
Study NCT06786845 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment lege artis
Description: Adequate treatment of sleep disorders at Sleep clinic
Study NCT04897438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney allograft biopsy depending on donor-derived cell-free DNA levels
Description: Kidney allograft biopsy is performed, when absolute levels of donor-derived cell-free DNA are above 50 copies/ml
Study NCT04983108 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention. This is an observational Study
Study NCT06310070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Personalized Ostomy Appliance
Description: Study procedures will include getting your stoma scanned, receiving personalized ostomy appliances in the mail, receiving a personalized ostomy template, which will be printed using a 3D printer, in the mail, and completing a daily symptom diary along with a weekly survey for 4 weeks.3D printing is done using a machine that takes the 3D image from the computer and prints a replica of the image using plastic or other materials.
Study NCT04970901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion
Study NCT04970901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: IV infusion
Study NCT04970901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: IV infusion
Study NCT04970901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Subcutaneous (SC) injection
Study NCT04970901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV infusion
Study NCT06501573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-9768
Description: SGB-9768 for sc injection
Study NCT06501573 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile normal saline (0.9% NaCl) for sc injection
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone
Description: Annual Influenza Vaccine
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Recombinant, adjuvanted Zoster Vaccine (RZV)
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flucelvax
Description: Annual Influenza Vaccine
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afluria
Description: Annual Influenza Vaccine
Study NCT04909515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: 3.0 mg/kg/day = 9.0 mg/kg/cycle
Study NCT04909515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 - 500 microgram/m2/day
Study NCT04909515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: 160 mg/m2/day
Study NCT05251636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Episcleral Brachytherapy
Description: Minimally invasive, single fraction brachytherapy
Study NCT05251636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Standard of Care intravitreal aflibercept injection
Study NCT05251636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection
Description: Standard of Care intravitreal aflibercept injection
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PREVNAR 13
Description: Pneumococcal Conjugate Vaccine (PCV13)
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heplisav -B
Description: Recombinant, adjuvanted Hepatitis (HepB-CpG)
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-COVID-19 Vaccine
Description: COVID-19 Vaccine
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluLaval
Description: Annual Influenza Vaccine
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Annual Influenza Vaccine
Study NCT06399016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: augmented reality book
Description: The story will be presented to the children in this application group in three dimensions. The augmented reality application will be supported by the researcher as it must be used under the supervision of an adult. When the tablet or phone is held to the pages of the book, the animations of these pages are displayed on the screen with sound. While the animation opens automatically when we hold the phone or tablet, the story can be listened to aloud at the same time.
Study NCT06399016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: book
Description: This group will be asked to just read the book without turning on the augmented reality feature of the book.
Study NCT06435039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202
Description: APL-1202 IR tablets.
Study NCT06435039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1501
Description: APL-1501 ER capsules.
Study NCT05573256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation
Description: Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.
Study NCT05573256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene education
Description: Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.
Study NCT04714645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR neglect training
Description: Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. The training consists of 5 different VR tasks specifically designed for neglect training.
Study NCT04714645 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VR control training
Description: Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. This is a placebo training, where patients will also wear the HMD. Patients will be immersed in a virtual environment without a specific task.
Study NCT05170399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX 23
Description: Pneumococcal Polysaccharide Vaccine (PPSV23)
Study NCT05170399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREVNAR 20
Description: Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
Study NCT05170399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AREXVY, ABRYSVO
Description: Respiratory Syncytial Virus Vaccine
Study NCT05519085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mezigdomide
Description: Specified dose on specified days
Study NCT05519085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Specified dose on specified days
Study NCT05519085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Specified dose on specified days
Study NCT05519085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study NCT05773573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The experimental group will have a hyrax rapid maxillary expander anchored on the 2nd deciduous molars (V)
Study NCT05773573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will have a hyrax rapid maxillary expander anchored on the 1st permanent molars (6)
Study NCT05476354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine low
Description: Irbesartan/Amlodipine low once daily for 8 weeks
Study NCT05476354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine high
Description: Irbesartan/Amlodipine high once daily for 8 weeks
Study NCT05476354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan once daily for 8 weeks
Study NCT05464420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Study NCT06084780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intestinal, Multivisceral or Modified Multivisceral Transplantation
Description: Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:~* Isolated small bowel transplant (SBT): transplantation of the donor small intestine~* Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach~* Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach
Study NCT06084780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
Study NCT06084780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
Study NCT05464420 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Study NCT06378203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele-rehabilitation system with virtual reality Home Kit - Virtual Reality Rehabilitation System (VRRS KHYMEIA)
Description: A personalized exercise plan following macro-areas of objectives:~* maintenance of muscle lengths with selective and/or prolonged static stretching exercises;~* maintenance/improvement of muscle trophism with selective and/or postural and/or functional muscle recruitment exercises at moderate intensity (approximately 65%-70% of the maximum);~* maintenance of respiratory muscle weakness with thoracic and/or diaphragmatic breathing exercises combined with muscle exercise;~* endurance training with walking, cycle ergometer (to be used with both the upper and lower limbs) and treadmill at moderate intensity (approximately 65%-70% of the maximum).~Home treatment will mostly take place with the KHYMEIA tele-rehabilitation system.
Study NCT04322084 — intervention group
Intervention type: OTHER
Intervention: Wearable Sensors
Description: To develop predictive algorithms that identify early onset of sepsis in children being treated for ALL. This study will use a two-stage design. The initial stage (the feasibility phase) will evaluate the feasibility of data collection, and the second stage (the completion phase) will provide data for the design of predictive models.
Study NCT04877990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT05264909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel Transcranial direct current stimulation
Description: A medical grade tDCS device will be use in this study (Star Stim TES, Neuroelectrics, Spain). The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
Study NCT05346354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight.~During the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight.
Study NCT06015230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dose GR1603 in phase Ⅰb
Description: 6 subjects in GR1603 low dose，2 subjects in placebo
Study NCT06015230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dose GR1603 in phaseⅠb
Description: 6 subjects in GR1603 high dose，2 subjects in placebo
Study NCT06015230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dose GR1603 in phase Ⅱ
Description: low dose GR1603 monthly
Study NCT06015230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dose GR1603 in phase Ⅱ
Description: high dose GR1603 monthly
Study NCT06015230 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in phase Ⅱ
Description: Placebo
Study NCT04875780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital diabetes prevention app intervention
Description: 16-week core program consisting of 16 online weekly interactive lessons on diet and physical activity for weight loss. After the completion of the core program, participant can proceed to the 36-week post-core phase. The post-core program provides 8 monthly lessons focusing on maintaining lifestyle habits and weight loss.~Participants will be guided to use the smartphone app for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 persons. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other.
Study NCT04875780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital weight loss tracking app intervention
Description: All participants will be provided the same smartphone app as the intervention group for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 person. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other.
Study NCT04875780 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list control (usual care)
Description: Participants in the control group will be invited to have an annual review and blood test at baseline, 4 and 12 months and received general lifestyle advices from a registered nurse at a community clinic.
Study NCT06084780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
Study NCT06102902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study NCT06102902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06102902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06102902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT06102902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06102902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06102902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO
Study NCT06102902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06102902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05891119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Oral liquid
Study NCT05891119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Oral tablet
Study NCT05891119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral liquid
Study NCT05891119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral tablet
Study NCT05891119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Oral tablet
Study NCT05891119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Oral capsule
Study NCT05891119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Subcutaneous injection
Study NCT04769206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: 4mg daily titrating up to 8mg twice a day
Study NCT04769206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill a day for 4 weeks, 2 pills a day for 8 weeks